Long-term drug treatment in multiple sclerosis: safety success and concerns

References

• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018 Apr 21;391(10130):1622–1636.
   PubMed Web of Science ®Google Scholar
• University of California SFMSET, Cree BA, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct;80(4):499–510.
   PubMed Web of Science ®Google Scholar
• Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019 Jun;15(6):329–342.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Kolb C, Ramanathan M, et al. Interferon beta for multiple sclerosis. Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003.
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010 Jan 05;74(Suppl 1):S17–24.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol. 1996 Mar;39(3):285–294.
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology. 1993 Apr;43(4):655–661.
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 07; 352(9139):1498–1504.
   PubMed Web of Science ®Google Scholar
• Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005 Aug;12(8):649–656.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Graf J, Kremer D. Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. J Neurol. 2020 Feb;267(2):308–316.
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006 Sep 26;67(6):944–953.
   PubMed Web of Science ®Google Scholar
• Reder AT, Oger JF, Kappos L, et al. Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Mult Scler Relat Disord. 2014 May;3(3):294–302.
   PubMed Web of Science ®Google Scholar
• Alba Pale L, Leon Caballero J, Samso Buxareu B, et al. Systematic review of depression in patients with multiple sclerosis and its relationship to interferonbeta treatment. Mult Scler Relat Disord. 2017 Oct;17:138–143.
   PubMed Web of Science ®Google Scholar
• Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler. 2005 Apr;11(2):175–181.
   PubMed Web of Science ®Google Scholar
• Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26(11):815–827.
   PubMed Web of Science ®Google Scholar
• Kowalec K, Kingwell E, Yoshida EM, et al. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf. 2014 Oct;13(10):1305–1317.
   PubMed Web of Science ®Google Scholar
• Kremenchutzky M, Morrow S, Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2007 May;6(3):279–288.
   PubMed Web of Science ®Google Scholar
• Lehmann HC, Kruger K, Fink GR, et al. Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. J Neurol. 2015 Mar;262(3):771–773.
   PubMed Web of Science ®Google Scholar
• Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014 Mar 27;370(13):1270–1271.
   PubMed Web of Science ®Google Scholar
• Ziliotto N, Bernardi F, Jakimovski D, et al. Coagulation pathways in neurological diseases: multiple sclerosis. Front Neurol. 2019;10:409.
   PubMed Web of Science ®Google Scholar
• de Jong HJI, Kingwell E, Shirani A, et al. Evaluating the safety of beta-interferons in MS: a series of nested case-control studies. Neurology. 2017 Jun 13;88(24):2310–2320.
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Kornmann G, Bischof D, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler. 2011 Apr;17(4):431–440.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Duarte Caron F, Wicklein EM, et al. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther Adv Neurol Disord. 2020;13:1756286420910310.
   Web of Science ®Google Scholar
• Hellwig K, Geissbuehler Y, Sabido M, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol. 2020 Feb 26;267(6):1715–1723.
   PubMed Web of Science ®Google Scholar
• Vaughn C, Bushra A, Kolb C, et al. An update on the use of disease-modifying therapy in pregnant patients with multiple sclerosis. CNS Drugs. 2018 Mar 5;32(2):161–178.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Nair KV, Glajch JL, et al. Two decades of glatiramer acetate: from initial discovery to the current development of generics. J Neurol Sci. 2017 May;15(376):255–259.
   Google Scholar
• Prod’homme T, Zamvil SS. The evolving mechanisms of action of glatiramer acetate. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249.
   PubMed Web of Science ®Google Scholar
• Ireland SJ, Guzman AA, O’Brien DE, et al. The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol. 2014 Nov;71(11):1421–1428.
   PubMed Web of Science ®Google Scholar
• Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157–14162.
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987 Aug 13;317(7):408–414.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology. 1995 Jul;45(7):1268–1276.
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31;374(9700):1503–1511.
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705–713.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand. 2005 Jan;111(1):42–47.
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010 Mar;16(3):342–350.
   PubMed Web of Science ®Google Scholar
• Ford C, Cohen J, Goodman A, et al. Twenty-five years of continuous treatment of multiple sclerosis with glatiramer acetate: long-term clinical results of the US open-label extension study. In: Mul Scler J. 25:285–285 .
   Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013 Jul;19(8):1074–1083.
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 Oct;7(10):903–914.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct;8(10):889–897.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: efficacy and safety results up to 7 years. Mult Scler Relat Disord. 2017 Nov;18:95–102.
   PubMed Web of Science ®Google Scholar
• Cohen J, Belova A, Selmaj K, et al. Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015 Dec;72(12):1433–1441.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14–24.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Ashtamker N, Rubinchick S, et al. Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf. 2017 Feb;16(2):247–255.
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration open-label extension study. Mult Scler. 2017 May;23(6):818–829.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Borresen TE, Dietrich DW, et al. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2015 Jul;4(4):370–376.
   PubMed Web of Science ®Google Scholar
• Halpern R, Wolbeck R, Blauer-Peterson C, et al. Adherence to glatiramer acetate 40 Mg versus oral disease-modifying therapies for multiple sclerosis. Value Health. 2015;18(7):A766.
   Web of Science ®Google Scholar
• Ziemssen T, Calabrese P, Penner IK, et al. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naive patients, and previously treated patients. J Neurol. 2016 Apr;263(4):784–791.
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018 Jan-Feb;20(1):9–14.
   PubMedGoogle Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941–5946.
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr;9(4):381–390.
   PubMed Web of Science ®Google Scholar
• Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015 Oct 8;373(15):1418–1428.
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22;381(9884):2167–2175.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May;13(5):472–481.
   PubMed Web of Science ®Google Scholar
• Gold R, Radue EW, Giovannoni G, et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26;16(1):117.
   PubMedGoogle Scholar
• Gold R, Radue EW, Giovannoni G, et al. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 May 25. DOI:10.1007/s00415-020-09835-y.
   Google Scholar
• Giovannoni G, Wiendl H, Turner B, et al. Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta. Mult Scler. 2018 Nov;24(13):1725–1736.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Kircik L, Hougeir F, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther. 2016 Jul;33(7):1231–1245.
   PubMed Web of Science ®Google Scholar
• Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016 Mar 1;86(9):847–855.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016 9;Sep:36–46.
   Google Scholar
• Stork L, Bruck W, von Gottberg P, et al. Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. Mult Scler. 2019 Oct;25(12):1618–1632.
   PubMed Web of Science ®Google Scholar
• Luessi F, Engel S, Spreer A, et al. GFAPalpha IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm. 2018 Sep;5(5):e481.
   PubMed Web of Science ®Google Scholar
• Carmenate T, Ortiz Y, Enamorado M, et al. Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells. J Immunol. 2018 May 15;200(10):3475–3484.
   PubMed Web of Science ®Google Scholar
• Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004 Jan 27;77(2):166–176.
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002 Apr 12;296(5566):346–349.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 04;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012 May;11(5):420–428.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Tenenbaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324.
   Web of Science ®Google Scholar
• Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016 May;87(5):468–475.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Sastre-Garriga J, Montalban X, et al. The ACROSS study: long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;Jan-Mar;6(1):2055217320907951.
   Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014 Apr;20(4):471–480.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan;72(1):31–39.
   PubMed Web of Science ®Google Scholar
• Achtnichts L, Obreja O, Conen A, et al. Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2015 Oct;72(10):1203–1205.
   PubMed Web of Science ®Google Scholar
• Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018 May 15;90(20):e1815–e1821.
   PubMed Web of Science ®Google Scholar
• DiMarco JP, O’Connor P, Cohen JA, et al. First-dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014 Sep;3(5):629–638.
   PubMed Web of Science ®Google Scholar
• Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014 Feb;261(2):267–276.
   PubMed Web of Science ®Google Scholar
• Limmroth V, Ziemssen T, Lang M, et al. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study. BMC Neurol. 2017 Jan 18;17(1):11.
   PubMed Web of Science ®Google Scholar
• Oo ML, Chang SH, Thangada S, et al. Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest. 2011 Jun;121(6):2290–2300.
   PubMed Web of Science ®Google Scholar
• Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul;120(7):1432–1439.
   PubMed Web of Science ®Google Scholar
• Ozel O, Vaughn CB, Eckert SP, et al. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: patient reported outcomes and perspectives. Patient Relat Outcome Meas. 2019;10:373–384.
   PubMed Web of Science ®Google Scholar
• Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018 Mar 29;360(6387):449–453.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098–1107.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017 Feb;23(2):253–265.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol. 2014 Sep;261(9):1794–1802.
   PubMed Web of Science ®Google Scholar
• Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015 Mar 17;84(11):1145–1152.
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020;13:1756286420915005.
   Web of Science ®Google Scholar
• Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016 Jan-Feb;18(1):9–18.
   PubMedGoogle Scholar
• Ochi H, Niino M, Onizuka Y, et al. 72-week safety and tolerability of dimethyl fumarate in japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. Adv Ther. 2018 Oct;35(10):1598–1611.
   PubMed Web of Science ®Google Scholar
• Phillips JT, Hutchinson M, Fox R, et al. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014 Jul;3(4):513–519.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020 Jan 17;34(2):185–196.
   PubMed Web of Science ®Google Scholar
• Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017 Jun;264(6):1155–1164.
   PubMed Web of Science ®Google Scholar
• Diebold M, Altersberger V, Decard BF, et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler. 2019 Oct;25(12):1682–1685.
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, Kappos L, Sprenger T. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Expert Opin Drug Saf. 2015 May;14(5):749–759.
   PubMed Web of Science ®Google Scholar
• Guan Y, Jakimovski D, Ramanathan M, et al. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res. 2019 Mar;14(3):373–386.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Bergsland N, Carl E, et al. Effect of teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: a retrospective, observational, case-control pilot study. J Clin Med. 2019 Mar 12;8(3):344.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293–1303.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247–256.
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Oct;13(10):977–986.
   PubMed Web of Science ®Google Scholar
• Kallmann BA, Tiel-Wilck K, Kullmann JS, et al. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;12:1756286419835077.
   Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014 May;20(6):705–716.
   PubMed Web of Science ®Google Scholar
• Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017 Oct;17:107–115.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. J Comp Eff Res. 2019 Apr;8(5):305–316.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012 Jun 5;78(23):1877–1885.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Wolinsky JS, Truffinet P, et al. A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2015;1:2055217315618687.
   Google Scholar
• Freedman MS, Morawski J, Thangavelu K. Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin. 2018 Apr-Jun;4(2):2055217318775236.
   Google Scholar
• Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012 Sep;18(9):1278–1289.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016 Mar 8;86(10):920–930.
   PubMed Web of Science ®Google Scholar
• Miller AE, Vermersch P, Kappos L, et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: results of the TOPIC extension study(bigstar bigstar). Mult Scler Relat Disord. 2019 Aug;33:131–138.
   PubMed Web of Science ®Google Scholar
• Comi G, Freedman MS, Kappos L, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016 Jan;5:97–104.
   PubMed Web of Science ®Google Scholar
• Lorefice L, Fenu G, Gerevini S, et al. PML in a person with multiple sclerosis: is teriflunomide the felon? Neurology. 2018 Jan 9;90(2):83–85.
   PubMed Web of Science ®Google Scholar
• Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol. 2008 Nov;65(11):1538–1539.
   PubMed Web of Science ®Google Scholar
• Vukusic S, Coyle PK, Jurgensen S, et al. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience. Mult Scler. 2019;10:1352458519843055.
   Google Scholar
• Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014 Dec;3(2):133–138.
   PubMedGoogle Scholar
• Hendin Travis L, Okai A, Cavalier S, et al. Real-world observational evaluation of hair thinning in patients with multiple sclerosis receiving teriflunomide: is it an issue in clinical practice? Neurol Ther. 2018 Dec;7(2):341–347.
   PubMed Web of Science ®Google Scholar
• Vacchiano V, Frattaruolo N, Mancinelli L, et al. Teeth loss after teriflunomide treatment: casual or causal? A short case series. Mult Scler Relat Disord. 2018 Aug;24:120–122.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999 Jan 23;353(9149):259–266.
   PubMed Web of Science ®Google Scholar
• Metzler C, Arlt AC, Gross WL, et al. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann Rheum Dis. 2005 Dec;64(12):1798–1800.
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics. 2017 Oct;14(4):874–887.
   PubMed Web of Science ®Google Scholar
• Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994 Jul 2;344(8914):9–13.
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group. Neurology. 2000 Mar 14;54(5):1145–1155.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416–426.
   PubMed Web of Science ®Google Scholar
• Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Mar;13(3):257–267.
   PubMed Web of Science ®Google Scholar
• Montalban X, Leist TP, Cohen BA, et al. Cladribine tablets added to IFN-beta in active relapsing MS: the ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep;5(5):e477.
   PubMed Web of Science ®Google Scholar
• Comi G, Cook SD, Giovannoni G, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol. 2013 Apr;260(4):1136–1146.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011 Apr;10(4):329–337.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018 Oct;24(12):1594–1604.
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005 Dec;58(6):840–846.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015 Dec;2(6):e158.
   PubMed Web of Science ®Google Scholar
• Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019 Apr;29:157–167.
   PubMed Web of Science ®Google Scholar
• Rosenberg JD, Burian C, Waalen J, et al. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014 Jan 9;123(2):177–183.
   PubMed Web of Science ®Google Scholar
• Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019 Apr;29:168–174.
   PubMed Web of Science ®Google Scholar
• Stuve O, Soelberg Soerensen P, Leist T, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986.
   Web of Science ®Google Scholar
• Alstadhaug KB, Fykse Halstensen R, Odeh F. Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. J Clin Virol. 2017 Mar;88:17–20.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Jakimovski D, Ahmed R, et al. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther. 2016 Sep;16(9):1151–1162.
   PubMed Web of Science ®Google Scholar
• Kivisakk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 2;72(22):1922–1930.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911–923.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009 Mar 3;72(9):806–812.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014 Jul 1;83(1):78–86.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri observational program (TOP). J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660–668.
   PubMed Web of Science ®Google Scholar
• Foley J, Carrillo-Infante C, Smith J, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord. 2019 Nov 21;39:101863.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 Mar 12;17(5):405–415.
   PubMed Web of Science ®Google Scholar
• Vukusic S, Rollot F, Casey R, et al. Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France. JAMA Neurol. 2020;77(1):94–102.
   PubMed Web of Science ®Google Scholar
• Gossai A, Waterboer T, Nelson HH, et al. Seroepidemiology of human polyomaviruses in a US population. Am J Epidemiol. 2016 Jan 1;183(1):61–69.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28;353(4):375–381.
   PubMed Web of Science ®Google Scholar
• Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017 Nov;16(11):925–933.
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014 Dec;76(6):802–812.
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Trojano M, Kappos L, et al. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) observational program (TOP). Mult Scler. 2020 May 14;1352458520917925.
   Web of Science ®Google Scholar
• Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology. 2015 Jul 7;85(1):29–39.
   PubMed Web of Science ®Google Scholar
• Leurs CE, van Kempen ZL, Dekker I, et al. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. Mult Scler. 2018 Oct;24(11):1453–1460.
   PubMed Web of Science ®Google Scholar
• John N, Carroll A, Brownlee WJ, et al. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1376–1378.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Hagemeier J, Kavak KS, et al. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry. 2016 Jan 18;87(9):937–943.
   Web of Science ®Google Scholar
• Kohlmann R, Salmen A, Chan A, et al. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Mult Scler. 2015 Dec;21(14):1823–1832.
   PubMed Web of Science ®Google Scholar
• Phillips JT, O’Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006 Nov 14;67(9):1717–1718.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 Oct 2;69(14):1391–1403.
   PubMed Web of Science ®Google Scholar
• de la Hera B, Urcelay E, Brassat D, et al. Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. Neurol Neuroimmunol Neuroinflamm. 2014 Dec;1(4):e47.
   PubMedGoogle Scholar
• Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013 Apr;19(5):593–600.
   PubMed Web of Science ®Google Scholar
• Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020 May;87(5):688–699.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829–1839.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1819–1828.
   PubMed Web of Science ®Google Scholar
• Investigators CT, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23;359(17):1786–1801.
   PubMed Web of Science ®Google Scholar
• Reddel SW, Barnett MH, Riminton S, et al. Successful implementation of an automated electronic support system for patient safety monitoring: the alemtuzumab in multiple sclerosis safety systems (AMS3) study. Mult Scler. 2019 Jul;25(8):1124–1131.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017 Sep 12;89(11):1107–1116.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017 Sep 12;89(11):1117–1126.
   PubMed Web of Science ®Google Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208–215.
   PubMed Web of Science ®Google Scholar
• Van Wijmeersch B, Singer BA, Boster A, et al. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: post hoc analysis of the CARE-MS studies. Mult Scler. 2019;1:1352458519881759.
   Google Scholar
• Buonomo AR, Zappulo E, Viceconte G, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018 Jul;17(7):709–717.
   PubMed Web of Science ®Google Scholar
• Wray S, Havrdova E, Snydman DR, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019 Oct;25(12):1605–1617.
   PubMed Web of Science ®Google Scholar
• Comi G, Alroughani R, Boster AL, et al. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. 2019;25:1352458519888610.
   Google Scholar
• Aguirre C, Meca-Lallana V, Sanchez P, et al. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord. 2019 Oct;35:270–271.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018 Jun;24(Suppl 2):S71–S82.
   PubMedGoogle Scholar
• Gerevini S, Capra R, Bertoli D, et al. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2019 Jul;25(8):1196–1201.
   PubMed Web of Science ®Google Scholar
• Katsavos S, Coles A. Alemtuzumab as treatment for multiple sclerosis. Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a032029.
   PubMed Web of Science ®Google Scholar
• Willis M, Robertson NP. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2014 Aug;13(8):1115–1124.
   PubMed Web of Science ®Google Scholar
• Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017 Aug 1;74(8):961–969.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Scolding NJ, Fox RJ. Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology. 2018 May 1;90(18):819–820.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Phillips R, Wass H, et al. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol. 2018 Nov;265(11):2494–2505.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Weinstock-Guttman B, Ramanathan M, et al. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opin Biol Ther. 2017 Sep;17(9):1163–1172.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Hauser S, Brochet B, Montalban X, et al. annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis (P1.366). Neurology. 2018;90(15Supplement):P1.366.
   PubMedGoogle Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–220.
   Google Scholar
• McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019 Jan;2(29):55–61.
   Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   Google Scholar
• Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis (P4.2-025). Neurology. 2019;92(15Supplement):P4.2–025.
   Google Scholar
• Sul J, Patel A, Gordon ML, et al. Progressive multifocal leukoencephalopathy in a patient on ocrelizumab monotherapy (4875). Neurology. 2020;94(15 Supplement):4875.
   Web of Science ®Google Scholar
• Dudek MIR, Thies K, Kammenhuber S, et al. HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab. J Neurol. 2019 Sep;266(9):2322–2323.
   PubMed Web of Science ®Google Scholar
• Nicolini LA, Canepa P, Caligiuri P, et al. Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis. JAMA Neurol. 2019 Jul 1;76(7):866–867.
   PubMed Web of Science ®Google Scholar
• Nylund M, Vuorinen T, Airas L. Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy. Mult Scler Relat Disord. 2020 Mar;14(42):102058.
   Google Scholar
• Derfuss T, Weber M, Hughes R, et al. Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. England: Sage Publications Ltd.;2019. p. 11–13.
   Google Scholar
• Jakimovski D, Weinstock-Guttman B, Ramanathan M, et al. Infections, vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines (Basel). 2020 Jan 28;8(1):E50.
   PubMed Web of Science ®Google Scholar
• Dirks P, Zingler V, Leemhuis J, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. BMC Neurol. 2020 Mar 14;20(1):95.
   PubMed Web of Science ®Google Scholar
• Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune diseases working party (ADWP) and the joint accreditation committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020 Feb;55(2):283–306.
   PubMed Web of Science ®Google Scholar
• Bose G, Thebault S, Rush CA, et al. Autologous hematopoietic stem cell transplantation for multiple sclerosis: a current perspective. Mult Scler. 2020 May 4;1352458520917936.
   Web of Science ®Google Scholar
• Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017 Apr 1;74(4):459–469.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019 Jan 15;321(2):165–174.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. Bone Marrow Transplant. 2020 Feb 4. DOI:10.1038/s41409-020-0810-z.
   Google Scholar
• Ge F, Lin H, Li Z, et al. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2019 Mar;40(3):479–487.
   PubMed Web of Science ®Google Scholar
• Curro D, Vuolo L, Gualandi F, et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult Scler. 2015 Oct;21(11):1423–1430.
   PubMed Web of Science ®Google Scholar
• Thebault S, Lee H, Bose G, et al. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann Clin Transl Neurol. 2020 Apr 18;7(5):767–775.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Martin R, Mancardi GL, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017 Jul;13(7):391–405.
   PubMed Web of Science ®Google Scholar
• Rush CA, Atkins HL, Freedman MS. Autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis. Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a029082.
   PubMed Web of Science ®Google Scholar
• Krasulova E, Trneny M, Kozak T, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler. 2010 Jun;16(6):685–693.
   PubMed Web of Science ®Google Scholar
• Frau J, Carai M, Coghe G, et al. Long-term follow-up more than 10 years after HSCT: a monocentric experience. J Neurol. 2018 Feb;265(2):410–416.
   PubMed Web of Science ®Google Scholar
• Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol. 2014 Mar;175(3):397–407.
   PubMed Web of Science ®Google Scholar
• Ng HS, Kingwell E, Zhu F, et al. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. Mult Scler. 2020;6:1352458520910500.
   Google Scholar
• Jakimovski D, Zivadinov R, Ramanthan M, et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study. Mult Scler. 2019;15:1352458519881428.
   Google Scholar
• Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019 Oct 8;93(15):e1452–e1462.
   PubMed Web of Science ®Google Scholar
• van Kempen ZL, Leurs CE, Witte BI, et al. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler. 2018 May;24(6):805–810.
   PubMed Web of Science ®Google Scholar
• Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885–889.
   PubMed Web of Science ®Google Scholar
• Baker PD, Pryce G, James LK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefitbalance in multiple sclerosis. Mult Scler Relat Disord. 2020;44:102279.
   PubMed Web of Science ®Google Scholar
• Zecca C, Merlini A, Disanto G, et al. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study. Mult Scler. 2018 Feb;24(2):167–174.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Guan Y, Ramanathan M, et al. Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegener Dis Manag. 2019 Jun;9(3):149–172.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Sondergaard HB, Laursen JH, et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler. 2018;2:1352458518791753.
   Google Scholar
• Kvistad SS, Myhr KM, Holmoy T, et al. Body mass index influence interferon-beta treatment response in multiple sclerosis. J Neuroimmunol. 2015 Nov;15(288):92–97.
   Web of Science ®Google Scholar
• Jakimovski D, Gandhi S, Paunkoski I, et al. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol. 2019 Jan;26(1):87–e8.
   PubMed Web of Science ®Google Scholar
• Kowalec K, Wright GEB, Drogemoller BI, et al. Common variation near IRF6 is associated with IFN-beta-induced liver injury in multiple sclerosis. Nat Genet. 2018 Jul 16;50(8):1081–1085.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Zivadinov R, Bergsland N, et al. Sex-specific differences in life span brain volumes in multiple sclerosis. J Neuroimaging. 2020 May;30(3):342–350.
   PubMed Web of Science ®Google Scholar
• Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.
   PubMed Web of Science ®Google Scholar
• Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler. 2010 Dec;16(12):1507–1512.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Salter A, Alster JM, et al. Risk tolerance to MS therapies: survey results from the NARCOMS registry. Mult Scler Relat Disord. 2015 May;4(3):241–249.
   PubMed Web of Science ®Google Scholar